OR WAIT null SECS
Japanese scientists have developed a new approach designed to overcome complexities of developing new, more effective drugs to treat diseases, including cancer.
Japanese scientists have developed a new approach designed to overcome complexities of developing new, more effective drugs to treat diseases, including cancer. This approach is focused on advancements in protein identification and quantification, which are reported to have been made possible by new-generation AB Sciex mass spectrometry technology and Eksigent chip-based nanoLC technology.
Dr Tetsuya Terasaki and his team at Tohoku University, Japan are claiming to identify and quantify a much wider range of drug transporter proteins, functional proteins and enzymes that activate or inactivate drugs in the body helping to accelerate the process of advancing protein biomarkers for future use in diagnostics.
Their research uses the AB Sciex TripleTOF 5600 System and Eksigent cHiPLC-nanoflex system, which the companies claim helps reproduce assays more easily than previously possible.
"AB Sciex promised to help us push the limits of pharmaceutical science, and they have done exactly that”, said Dr Terasaki. “With the support of AB Sciex we are accelerating biomedical research to develop new paths to drug discovery and development intended to improve diagnostics and treatment for the good of humanity."
For more information on these products visit www.absciex.com